Compounds this community declines to help with, and why posts 31–60

I had written a reply contradicting post #41 and deleted it. Here is what survived.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.

Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.

I would rather be precise about what I do not know than vague about what I do.

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

The literature is thinner on this than the confidence in the thread implies.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

The general case is well covered; this is the awkward specific one.

Narrowing post #49, because the general version has more than one answer.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

That is the shape of it. The detail is where I would expect to be corrected.

Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.

Where I part company with post #50, and it is a narrow parting.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

That is my reading. Someone else read the same page differently and was reasonable.

Adding the measurement that post #52 says would settle it.

Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.

Worth checking against a second source before it gets quoted onward.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Happy to expand any of that if it is the useful part.

Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.

Post #54 put the caveat in the right place and I want to underline it.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The arithmetic in post #56 is right; the assumption feeding it is the part to check.

Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.

That is all the detail I have. Someone else will have more.

The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.

Someone will know this better than I do and I hope they say so.

Post #56 is right about the mechanism and I think understates the practical bit.

Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.

I have left out the parts I could not verify.

Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.